arrow
R

Ruth E. Langley

Maastricht University Medical Centre
H指数:42
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role of DNA mismatch repair status in oesophagogastric cancer treated with perioperative chemotherapy: evidence from the MRC ST03 and OE05 trials

DNA错配修复状态在围手术期化疗治疗的食管胃癌中的角色:来自MRC ST03和OE05试验的证据

2026-08-250
OA
Validation of tumour-negative lymph node size as a novel independent prognostic biomarker in oesophagogastric adenocarcinoma: post hoc analysis of the UK MRC OE05 and ST03 randomised trials

肿瘤阴性淋巴结大小作为食管胃腺癌的新型独立预后生物标志物的验证:英国MRC OE05和ST03随机试验的事后分析

2026-08-010
OAAI
The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients – Results from the UK MRC OE02 trial

食管癌患者区域淋巴结微结构的临床相关性——来自英国MRC OE02试验的结果

2026-06-290
OAAI
Authors’ reply: "Healthcare systems data (HSD) to improve the efficiency of clinical trials within the UK: A prospectively planned comparison of HSD and trial-reported outcomes within the Add-Aspirin cancer clinical trial"

作者回复:“利用卫生保健系统数据(HSD)以提高英国临床试验的效率:一项前瞻性计划的比较,比较Add-Aspirin癌症临床试验中的HSD和试验报告结果”

2026-05-280
PRE
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer

局部晚期前列腺癌的经皮雌二醇贴剂

2026-03-012
PRE
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

二甲双胍用于开始接受雄激素剥夺治疗的转移性前列腺癌患者:一项STAMPEDE平台方案的随机III期试验

2025-07-070
OAAI
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis

术前放化疗与化疗治疗食管胃结合部腺癌的网状Meta分析

2024-08-021
OAAI
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials

性别对局部晚期微卫星不稳定性高的胃或胃食管交界癌的预后和预测影响: 一项随机临床试验的个体患者数据汇总分析

2024-05-010
PRE
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
2024-01-015
OAAI
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial

基质活跃侵袭前区 (SARIFA) 可改善MAGIC和ST03试验围手术期化疗治疗的食管胃癌患者的预后风险分层

2023-12-204
OA